5 Message from our Chairman Dear Stakeholders, We consider ourselves as a value creator in the New Chemical Entity (NCE) discovery, development and commercialisation supply chain. Drug discovery pursuits require nurturing a mindset of trust and collaboration along with a network of talent and expertise. We are immensely proud that we engage in sustainable growth through our contribution to the drug discovery pipeline while partnering with innovator pharma companies, biotechs, start-ups and academic institutions. A significant amount of work is happening globally to improve the ability to predict the clinical success of a drug candidate. Collecting and curating high-quality data across the drug discovery process is creating immense value for humanity. Yet the list of unmet therapeutic needs remains long. The challenges are huge, and despite COVID-19 pandemic-related uncertainties in the reporting period, we moved up the steep curve by investing and embracing new technologies and a wide range of expertise to drive speed and decisively handle complexity. The investment we have made in creating what our global innovator partners expect in their in-house facilities, as part of Sai Nxt, is finding resonance with our customers and partners. I believe that we will continue to make a difference. Starting as a chemistry services provider in 1999, we have now gone well beyond chemistry and have over 60% of our work comprising of integrated services. Our capable team of synthetic and medicinal chemists and biologists have a successful track record of delivering 15 sponsor programs from initial discovery to IND and delivering an impressive 95%+ of all molecules requested. In addition, we have seen a shift towards programs moving out of discovery and into CMC, with outsourcing companies being comfortable with the culture and capability fit of Sai with their organisations. Forging a path through discovery and into development with the same integrated partner where a good relationship, expertise and capabilities exist helps us holistically contribute to meeting unmet patient needs. Sustainability success is a promise as we pursue our growth plans of achieving further scale, scope and speed while consciously integrating our environmental, social and governance responsibilities. I know we have organised our strategy, culture and day-to-day operations keeping sustainability at the core. It is a shared responsibility encompassing all our key stakeholders and my heartfelt appreciation for their commitment and perseverance. I am very excited and look forward to a promising 2022. There could be more challenges and uncertainties. Yet we are unfazed as our endeavours are aligned and drawn from the question “What’s the impact of our actions on the lives of patients and society?” We will always seek to understand patient needs and work with our key stakeholders to bring the best solutions forward. We know that there is a lot to do and we commit to working responsibly year after year, going above and beyond. Sincerely, K Ranga Raju Chairman
RkJQdWJsaXNoZXIy MTIwMDc4NQ==